Myomo to Report Fourth Quarter and Year End 2018 Results on March 7, 2019

February 28, 2019 |

2 min read

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2018 on Thursday, March 7, 2019, after the US markets close.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc., (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2018 on Thursday, March 7, 2019, after the US markets close.

The Company will host a conference call on Thursday, March 7, 2019 at 4:30 p.m. EST featuring remarks by Paul R. Gudonis, Chairman and Chief Executive Officer, and David Henry, Chief Financial Officer. The conference call, webcast and accompanying slides can be accessed through Myomo’s Investor Relations page. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

To dial into the conference call, please dial 1-877-270-2148 from the U.S. or 1-412-902-6510 internationally. A replay of the conference call will be available approximately one hour after completion of the live conference call at the Investor Relations page. A dial-in replay of the call will be available until March 21, 2019; please dial 1-877-344-7529 from the U.S. or 1-412-317-0088 internationally and provide the passcode of 10129136.

About Myomo
Myomo, Inc. is a wearable medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S. For more information, please visit www.myomo.com.